EUVIMEDOpdag EUVIMED
Crossref

Utilization of dd‐cfDNA Monitoring to Facilitate Immunosuppression Minimization After Kidney Transplantation in a U.S. Veteran Population

Laura Cotiguala iD, Anne Przybylski iD, Cara Joyce iD, Gabrielle Hansen iD, Nicholas Shah, Reynold I Lopez-Soler iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026

DOI: 10.1002/phar.70102 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Written by Laura Cotiguala and 5 co-authors. Institution: Edward Hines Jr. VA Hospital, Hines, Illinois, USA. Major MEDLINE topics: Kidney Transplantation, Immunosuppressive Agents, Graft Rejection, Cell-Free Nucleic Acids. 23 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Although donor‐derived cell‐free DNA (dd‐cfDNA) serves as a monitoring tool for rejection, few studies have examined its utility in guiding immunosuppression management. Here, we present the largest kidney transplant population in which immunosuppression minimization and subsequent surveillance were guided by dd‐cfDNA.

Methods

This retrospective case series evaluated our immunosuppression minimization practice to tacrolimus and prednisone in kidney transplant recipients (KTR) from November 20, 2020, to September 26, 2024. Baseline dd‐cfDNA ≤ 0.5% was required before minimization. Immune tolerance was defined by the absence of any immune event after minimization: absolute dd‐cfDNA > 0.5%, relative change value (RCV) > 60% from baseline, biopsy‐proven acute rejection (BPAR), or de novo donor‐specific antibody (DSA). All other KTR were labeled intolerant. The primary endpoint was the rate of immune tolerance.

Results

Immunosuppression was modified to tacrolimus and prednisone in 38 KTR at a median of 223 days post‐transplant. Most KTR were older adults at low immunological risk: mean of 69 years and all had a calculated panel reactive antibody of 0%. 21 (55.3%) KTR met the primary end point of tolerance. The remaining 17 KTR were labeled intolerant secondary to dd‐cfDNA elevations including absolute > 0.5% or RCV > 60% ( n = 16 of 17, 94%), de novo DSA ( n = 2 of 17, 11.8%), and/or BPAR ( n = 4 of 17, 23.5%). Although not statistically significant, intolerant KTR were numerically more likely to have 5–6 HLA mismatches (82.5% vs. 52.4%, p = 0.31), less likely to have thymoglobulin induction (29.4% vs. 42.9%, p = 0.39), and were minimized earlier after transplant (196 vs. 256 days, p = 0.08) compared with tolerant KTR, respectively. Intervention after dd‐cfDNA elevations included immunosuppression increase (50%), additional dd‐cfDNA monitoring (81.3%), DSA testing (50%), and allograft biopsy (18.7%).

Conclusion

Approximately 50% of low immunological risk KTR with a baseline dd‐cfDNA < 0.5% tolerated immunosuppression minimization to tacrolimus and prednisone without concerning dd‐cfDNA elevations, BPAR, or DSA. Our study highlights the role of dd‐cfDNA as part of the armamentarium for identifying minimization candidates and performing subsequent surveillance.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationImmunosuppressive AgentsGraft RejectionCell-Free Nucleic AcidsHumansRetrospective StudiesTacrolimusFemalePrednisoneMaleMiddle AgedAgedImmunosuppression TherapyImmune ToleranceUnited States

Author keywords

dd‐cfDNAimmunosuppression minimizationkidney transplant

Substances

Immunosuppressive AgentsTacrolimusPrednisoneCell-Free Nucleic Acids

Authors and institutions

  • Edward Hines Jr. VA Hospital, Hines, Illinois, USA.
  • Loyola University Medical Center, Maywood, Illinois, USA.

ORCID profiles: Laura Cotiguala, Anne Przybylski, Cara Joyce, Gabrielle Hansen, Reynold I Lopez-Soler

Cite

APA

Cotiguala, L., Przybylski, A., Joyce, C., Hansen, G., Shah, N., & Lopez-Soler, R. I. (2026). Utilization of dd‐cfDNA Monitoring to Facilitate Immunosuppression Minimization After Kidney Transplantation in a U.S. Veteran Population. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70102

Vancouver

Cotiguala L, Przybylski A, Joyce C, Hansen G, Shah N, Lopez-Soler RI. Utilization of dd‐cfDNA Monitoring to Facilitate Immunosuppression Minimization After Kidney Transplantation in a U.S. Veteran Population. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70102

BibTeX
@article{Cotiguala2026,
  author = {Cotiguala, Laura and Przybylski, Anne and Joyce, Cara and Hansen, Gabrielle and Shah, Nicholas and Lopez-Soler, Reynold I},
  title = {Utilization of dd‐cfDNA Monitoring to Facilitate Immunosuppression Minimization After Kidney Transplantation in a U.S. Veteran Population},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  doi = {10.1002/phar.70102}
}
Start for free →